Eur Urol:高风险局部和局部晚期肾细胞癌手术切除后的疾病复发、早期进展和总生存率预测

2021-03-20 AlexYang MedSci原创

局部肾细胞癌(RCC)的风险分层严重依赖于回顾性模型,限制了其对当代队列的可推广性。

局部肾细胞癌(RCC)的风险分层严重依赖于回顾性模型,限制了其对当代队列的可推广性。

最近,有研究人员介绍了一个当代RCC预后模型,使用了一个III期辅助试验的前瞻性和高度注释的数据

研究共有1735名患者被纳入分析,在中位随访时间为9.6年中发生了887个DFS事件。每个模型中都包含了五个常见的肿瘤变量(组织学、大小、等级、肿瘤坏死和结节受累)。研究发现,肿瘤组织学是每个模型结果最有力的单一预测因素。1年后的C统计学DFS和OS分别为78.4%和81.9%。随着时间的推移,DFS、DFS验证集和OS模型的判别能力出现退化,全局c-指数分别为68.0%(95%CI [65.5%,70.4%])、68.6%(95%CI [65.1%,72.2%])和69.4%(95%CI [66.9%,71.9%]。EDP模型的c指数为75.1%(95%CI [71.3,79.0])。

最后,研究人员指出,他们引入了一个当代的RCC复发模型,并利用临床试验的前瞻性和高度注释的数据进行了内部验证。当前模型的性能特征超过了现有的预后模型,并具有组织学包容性和TNM不可知的额外优势

原始出处:

Andres F Correa, Opeyemi A Jegede, Naomi B Haas et al. Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma. Eur Urol. Mar 2021

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1862152, encodeId=678b1862152e4, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Fri Dec 17 04:55:27 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650794, encodeId=c37d1650e94c4, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Wed May 19 19:55:27 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798893, encodeId=adb61e9889398, content=<a href='/topic/show?id=b677e06626a' target=_blank style='color:#2F92EE;'>#疾病复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70662, encryptionId=b677e06626a, topicName=疾病复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Fri Nov 26 07:55:27 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979097, encodeId=0f1119e9097b9, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Wed Jun 16 01:55:27 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256821, encodeId=e73a125682161, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406033, encodeId=1681140603381, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429441, encodeId=3f9c142944143, content=<a href='/topic/show?id=bb015438221' target=_blank style='color:#2F92EE;'>#手术切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54382, encryptionId=bb015438221, topicName=手术切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdd4195665, createdName=s_pl2009, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441764, encodeId=6a791441e6432, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59875, encryptionId=09a6598e57a, topicName=晚期肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87304889998, createdName=12498c24m70暂无昵称, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1862152, encodeId=678b1862152e4, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Fri Dec 17 04:55:27 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650794, encodeId=c37d1650e94c4, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Wed May 19 19:55:27 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798893, encodeId=adb61e9889398, content=<a href='/topic/show?id=b677e06626a' target=_blank style='color:#2F92EE;'>#疾病复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70662, encryptionId=b677e06626a, topicName=疾病复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Fri Nov 26 07:55:27 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979097, encodeId=0f1119e9097b9, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Wed Jun 16 01:55:27 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256821, encodeId=e73a125682161, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406033, encodeId=1681140603381, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429441, encodeId=3f9c142944143, content=<a href='/topic/show?id=bb015438221' target=_blank style='color:#2F92EE;'>#手术切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54382, encryptionId=bb015438221, topicName=手术切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdd4195665, createdName=s_pl2009, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441764, encodeId=6a791441e6432, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59875, encryptionId=09a6598e57a, topicName=晚期肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87304889998, createdName=12498c24m70暂无昵称, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1862152, encodeId=678b1862152e4, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Fri Dec 17 04:55:27 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650794, encodeId=c37d1650e94c4, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Wed May 19 19:55:27 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798893, encodeId=adb61e9889398, content=<a href='/topic/show?id=b677e06626a' target=_blank style='color:#2F92EE;'>#疾病复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70662, encryptionId=b677e06626a, topicName=疾病复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Fri Nov 26 07:55:27 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979097, encodeId=0f1119e9097b9, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Wed Jun 16 01:55:27 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256821, encodeId=e73a125682161, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406033, encodeId=1681140603381, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429441, encodeId=3f9c142944143, content=<a href='/topic/show?id=bb015438221' target=_blank style='color:#2F92EE;'>#手术切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54382, encryptionId=bb015438221, topicName=手术切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdd4195665, createdName=s_pl2009, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441764, encodeId=6a791441e6432, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59875, encryptionId=09a6598e57a, topicName=晚期肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87304889998, createdName=12498c24m70暂无昵称, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1862152, encodeId=678b1862152e4, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Fri Dec 17 04:55:27 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650794, encodeId=c37d1650e94c4, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Wed May 19 19:55:27 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798893, encodeId=adb61e9889398, content=<a href='/topic/show?id=b677e06626a' target=_blank style='color:#2F92EE;'>#疾病复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70662, encryptionId=b677e06626a, topicName=疾病复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Fri Nov 26 07:55:27 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979097, encodeId=0f1119e9097b9, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Wed Jun 16 01:55:27 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256821, encodeId=e73a125682161, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406033, encodeId=1681140603381, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429441, encodeId=3f9c142944143, content=<a href='/topic/show?id=bb015438221' target=_blank style='color:#2F92EE;'>#手术切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54382, encryptionId=bb015438221, topicName=手术切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdd4195665, createdName=s_pl2009, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441764, encodeId=6a791441e6432, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59875, encryptionId=09a6598e57a, topicName=晚期肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87304889998, createdName=12498c24m70暂无昵称, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1862152, encodeId=678b1862152e4, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Fri Dec 17 04:55:27 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650794, encodeId=c37d1650e94c4, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Wed May 19 19:55:27 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798893, encodeId=adb61e9889398, content=<a href='/topic/show?id=b677e06626a' target=_blank style='color:#2F92EE;'>#疾病复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70662, encryptionId=b677e06626a, topicName=疾病复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Fri Nov 26 07:55:27 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979097, encodeId=0f1119e9097b9, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Wed Jun 16 01:55:27 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256821, encodeId=e73a125682161, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406033, encodeId=1681140603381, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429441, encodeId=3f9c142944143, content=<a href='/topic/show?id=bb015438221' target=_blank style='color:#2F92EE;'>#手术切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54382, encryptionId=bb015438221, topicName=手术切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdd4195665, createdName=s_pl2009, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441764, encodeId=6a791441e6432, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59875, encryptionId=09a6598e57a, topicName=晚期肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87304889998, createdName=12498c24m70暂无昵称, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1862152, encodeId=678b1862152e4, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Fri Dec 17 04:55:27 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650794, encodeId=c37d1650e94c4, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Wed May 19 19:55:27 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798893, encodeId=adb61e9889398, content=<a href='/topic/show?id=b677e06626a' target=_blank style='color:#2F92EE;'>#疾病复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70662, encryptionId=b677e06626a, topicName=疾病复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Fri Nov 26 07:55:27 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979097, encodeId=0f1119e9097b9, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Wed Jun 16 01:55:27 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256821, encodeId=e73a125682161, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406033, encodeId=1681140603381, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429441, encodeId=3f9c142944143, content=<a href='/topic/show?id=bb015438221' target=_blank style='color:#2F92EE;'>#手术切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54382, encryptionId=bb015438221, topicName=手术切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdd4195665, createdName=s_pl2009, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441764, encodeId=6a791441e6432, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59875, encryptionId=09a6598e57a, topicName=晚期肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87304889998, createdName=12498c24m70暂无昵称, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=)]
    2021-03-22 chg122
  7. [GetPortalCommentsPageByObjectIdResponse(id=1862152, encodeId=678b1862152e4, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Fri Dec 17 04:55:27 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650794, encodeId=c37d1650e94c4, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Wed May 19 19:55:27 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798893, encodeId=adb61e9889398, content=<a href='/topic/show?id=b677e06626a' target=_blank style='color:#2F92EE;'>#疾病复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70662, encryptionId=b677e06626a, topicName=疾病复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Fri Nov 26 07:55:27 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979097, encodeId=0f1119e9097b9, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Wed Jun 16 01:55:27 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256821, encodeId=e73a125682161, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406033, encodeId=1681140603381, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429441, encodeId=3f9c142944143, content=<a href='/topic/show?id=bb015438221' target=_blank style='color:#2F92EE;'>#手术切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54382, encryptionId=bb015438221, topicName=手术切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdd4195665, createdName=s_pl2009, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441764, encodeId=6a791441e6432, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59875, encryptionId=09a6598e57a, topicName=晚期肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87304889998, createdName=12498c24m70暂无昵称, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1862152, encodeId=678b1862152e4, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Fri Dec 17 04:55:27 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650794, encodeId=c37d1650e94c4, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Wed May 19 19:55:27 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798893, encodeId=adb61e9889398, content=<a href='/topic/show?id=b677e06626a' target=_blank style='color:#2F92EE;'>#疾病复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70662, encryptionId=b677e06626a, topicName=疾病复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Fri Nov 26 07:55:27 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979097, encodeId=0f1119e9097b9, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Wed Jun 16 01:55:27 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256821, encodeId=e73a125682161, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406033, encodeId=1681140603381, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429441, encodeId=3f9c142944143, content=<a href='/topic/show?id=bb015438221' target=_blank style='color:#2F92EE;'>#手术切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54382, encryptionId=bb015438221, topicName=手术切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdd4195665, createdName=s_pl2009, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441764, encodeId=6a791441e6432, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59875, encryptionId=09a6598e57a, topicName=晚期肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87304889998, createdName=12498c24m70暂无昵称, createdTime=Mon Mar 22 03:55:27 CST 2021, time=2021-03-22, status=1, ipAttribution=)]

相关资讯

BJU Int:系统靶向治疗复发性肾细胞癌中的辅助舒尼替尼治疗结果

目前还没有现有数据支持系统性靶向治疗(TT)复发肾细胞癌(RCC)患者在完成舒尼替尼辅助治疗后的可能反应。最近,有研究人员评估了在晚期阶段再次使用舒尼替尼和其他TT的有效性和耐受性。

ASCO GU 2021: 免疫联合靶向在晚期肾癌中大获成功,完成2年治疗的人群结果公布(KEYNOTE-426研究)

在过去的两年中,转移性肾细胞癌(mRCC)患者一线治疗的治疗方式发生了巨大变化。 2018年,CheckMate214数据的发布证明,在中度和低危mRCC中,与舒尼替尼相比,用nivolumab和ip

ASCO GU 2021: Nivolumab联合Cabozantinib与舒尼替尼在晚期肾细胞癌中效果对比(CheckMate 9ER研究)

在过去的两年中,转移性肾细胞癌(mRCC)患者一线治疗的治疗方式发生了巨大变化。 2018年,CheckMate214数据的发布表明,在中度和低风险的mRCC中,与舒尼替尼相比,用nivolumab和

Eur Urol Focus:种族/民族影响手术治疗的肾细胞癌患者的预期寿命

预期寿命(LE)是T1aN0M0肾细胞癌(RCC)患者临床决策的重要考虑因素。

J Clin Oncol:Pembrolizumab单抗作为晚期非透明细胞肾细胞癌患者一线治疗的开放标签、单臂、II期研究

程序性死亡1(PD-1)通路抑制剂尚未在非透明细胞肾细胞癌(nccRCC)患者中进行前瞻性评估。

Sci Rep:循环肿瘤DNA作为转移性肾细胞癌中免疫检查点阻断治疗反应的预测因子表现研究

最近,有研究人员在接受免疫检查点阻断(ICB)治疗的转移性肾细胞癌(mRCC)患者中,通过靶向深度测序检测循环肿瘤DNA(ctDNA),评估了其预测作用。